Overview
- A local unit, TAL Daiichi Life Australia Pty, has proposed to buy the remaining more than 79% of Challenger shares at A$11.80 each, valuing the company at about A$7.94 billion and offering roughly a 20% premium to recent trading levels.
- The proposal is explicitly indicative and conditional, requiring satisfactory due diligence and any necessary shareholder or regulatory approvals before a binding deal could be reached.
- Market data show TAL already holds a substantial stake in Challenger, reported at about 20.36%, after an earlier purchase of 15.1% from MS&AD in 2025 that underpinned this move to seek control.
- Challenger’s board is evaluating the offer and Daiichi Life had not provided an immediate public comment; Challenger separately reported a 5% rise in assets under management to $31.9 billion for Q1 FY2027 driven by strong annuities sales.
- If the sale proceeds, Daiichi Life would expand its overseas footprint and gain direct access to Australia’s fast-growing retirement and annuities market, with next steps likely to include detailed due diligence, negotiation of a binding bid, and regulatory review.